The Latest Breaking News from AstraZeneca

Most people will have the Moderna or the Pfizer vaccine for their fourth dose. But the Doherty Institute's head of vaccine and immunisation research says there's practically no difference between them.

The Ministry of Public Health on Wednesday signed a procurement agreement with AstraZeneca for 257,500 doses of the long-acting antibody drug Evusheld, which boosts Covid-19 immunity in patients with low immunity levels.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Oxford Biomedica plc (OTC:OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc's (NASDAQ:AZN) COVID-19 vaccine beyond 2022. The new agreement represents an expansion of the original master supply and development agreement announced between the two companies in September 2020. The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility, as part of the…

As Australia approaches the grim milestone of 10,000 Covid deaths, we look at the people behind the numbers

The family of Katie Lees, who died after receiving a COVID-19 vaccine, say an arts fellowship in her name "lifts" them from being stuck in horror and grief, as they wait for clarity on an inquiry into the vaccine rollout.

AstraZeneca is trying to break out of a new base as earnings growth appears to be on the upswing.

The Dow Jones rose despite Fed Chair Jerome Powell issuing an inflation warning. Tesla stock fell amid closure news. Apple stock rose.

The Nasdaq composite is down 0.5%, while the S&P 500 is down 0.4%. The Russell 2000 is down 1.7%.